GLP-1 receptor agonist (public encyclopedia provenance reconstruction)
Reconstructed from 22 public encyclopedia revisions showing article evolution
22 revisions 3 claim families 14 variants 9 events
This is a test of the reconstruction, not a reading of an asset: whether one claim can be held as the same claim through years of public edits, whether related statements group into stable families, whether the places the record was disputed or weakened show up, and whether a second analyst working independently lands on the same families. Every statement keeps the revision it came from, so any of it can be checked.
The source is a public encyclopedia's revision history. Its dated revisions let readers check the reconstruction against individual edits. This is a test corpus for the method; registered forecasts use their own source evidence.
Illustrative. Nothing here is a recommendation for clinical or institutional action, and none of it is a registered forecast. Download the artifact as JSON.
Independent assertion extraction and claim-family grouping by two analysts, with disagreements resolved by documented criteria.
Documented disagreement
Disagreement: Bridge process split a drug-list assertion into two families because word overlap fell below the 0.5 threshold; human analyst treated it as one semantic family.
Resolution: Added section-anchored joining: merge assertions in the same section when overlap > 0.3.
The full artifact: assessments, claim families, events, review decisions, reliance, citations
The evidence under the claim moved across the reviewed revisions. The claim as written may no longer describe what the sources support.
- Movement in the record: moderate, read across 3 claim groups and 3 assessed sources.
- How much rests on the claim: strong, from 1 endorsement and 2 operational uses found in the sources.
- Signs of support and restriction in the sources: strong.
| Family | Direction | Variants | Disputes | Last change | Basis |
|---|---|---|---|---|---|
| fam-sentence-1 | disputed | 3 | 1 | 2012-08-22 | analyst asserted |
| fam-sentence-2 | mixed | 7 | 0 | 2012-09-27 | analyst asserted |
| fam-sentence-3 | mixed | 4 | 0 | 2012-09-27 | analyst asserted |
One of their advantages is that they have a lower risk of ca...
Relationships
Licenced : exenatide (2005) Under investigation : liragluti...
Relationships
Glucagon-like peptide-1 agonists (GLP-1 agonists) are new cl...
Relationships
Reverted edits by [[Special:Contributions/59.95.72.254|59.95.72.254]] ([[User talk:59.95.72.254|talk]]) to last revision by PhiLiP ([[WP:HG|HG]])
FDA approval provides direct institutional operationalization of the class-level T2D claim.
Add liraglutide to the list of licensed GLP-1 agonists without changing the family scope.
Endorsement supports the class claim but is inferred from guideline language, not an operational record; retain with ASCVD qualification.
FDA approval converts the evidence claim "GLP-1 agonists are a class of drugs for type 2 diabetes" into an operational regulatory commitment for exenatide.
FDA approval extends the operational commitment to another GLP-1 agonist, supporting the family that exenatide and liraglutide are licensed options.
ADA Standards of Care endorse GLP-1 receptor agonists for type 2 diabetes, particularly when atherosclerotic cardiovascular disease is present. This is an endorsement inferred from guideline language, not an operational record of a specific institution acting on it.
Changes in related examples can add context to this claim history. These links show where a source event in one domain creates a question for a related claim.
FDA approval of liraglutide for chronic weight management strengthens the cross-specimen claim that GLP-1-class drugs, including liraglutide, have an obesity/weight-management indication.
The GLP-1 class ADA endorsement supports the liraglutide T2D mechanism claim because liraglutide is a member of the endorsed class.
Evidentiary
- Public encyclopedia version identifiers
- Edit timestamps
- Editor usernames
- Edit comments
- Citation URLs
- Page move records
- Template changes
Derived
- Sentence-level diffs (before/after)
- Citation added/removed events
- Section reorganization events
- Edit magnitude (minor/moderate/major)
- Content change type
- Key terms extraction
- Direction signal (strengthening/weakening/neutral)
Inferred
- Claim family membership
- Claim variant relationships
- Confidence assignment
- Impact direction
- Decision rationale reconstruction
- Reliance commitment interpretation